Inovio Pharmaceuticals Inc (INO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inovio Pharmaceuticals Inc (INO) has a cash flow conversion efficiency ratio of 2.795x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.57 Million) by net assets ($-7.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Inovio Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Inovio Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Inovio Pharmaceuticals Inc (INO) total liabilities for a breakdown of total debt and financial obligations.
Inovio Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inovio Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Billion Electric Co Ltd
TW:3027
|
-0.017x |
|
QPM Energy Ltd
AU:QPM
|
0.164x |
|
Hana Must SPAC 2
KQ:208370
|
0.013x |
|
Ak Holdings
KO:006840
|
0.084x |
|
United Polyfab Gujarat Limited
NSE:UNITEDPOLY
|
0.101x |
|
Infant Bacterial Therapeutics AB (publ)
ST:IBT-B
|
-0.420x |
|
Apollo Power Ltd
TA:APLP
|
-0.074x |
|
Yusin Holding Corp
TW:4557
|
0.042x |
Annual Cash Flow Conversion Efficiency for Inovio Pharmaceuticals Inc (1998–2024)
The table below shows the annual cash flow conversion efficiency of Inovio Pharmaceuticals Inc from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see Inovio Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $68.50 Million | $-104.08 Million | -1.519x | -43.36% |
| 2023-12-31 | $117.35 Million | $-124.37 Million | -1.060x | -8.99% |
| 2022-12-31 | $222.36 Million | $-216.22 Million | -0.972x | -80.16% |
| 2021-12-31 | $399.67 Million | $-215.71 Million | -0.540x | -39.84% |
| 2020-12-31 | $461.14 Million | $-177.98 Million | -0.386x | +97.87% |
| 2019-12-31 | $5.40 Million | $-97.85 Million | -18.104x | -2042.27% |
| 2018-12-31 | $87.03 Million | $-73.55 Million | -0.845x | -90.50% |
| 2017-12-31 | $142.49 Million | $-63.21 Million | -0.444x | +12.51% |
| 2016-12-31 | $123.38 Million | $-62.56 Million | -0.507x | -617.11% |
| 2015-12-31 | $175.93 Million | $-12.44 Million | -0.071x | +73.56% |
| 2014-12-31 | $111.54 Million | $-29.82 Million | -0.267x | +8.04% |
| 2013-12-31 | $52.90 Million | $-15.38 Million | -0.291x | +54.57% |
| 2012-12-31 | $34.86 Million | $-22.31 Million | -0.640x | -55.04% |
| 2011-12-31 | $47.86 Million | $-19.76 Million | -0.413x | -62.86% |
| 2010-12-31 | $47.10 Million | $-11.94 Million | -0.253x | -10.13% |
| 2009-12-31 | $61.18 Million | $-14.08 Million | -0.230x | +60.48% |
| 2008-12-31 | $19.11 Million | $-11.13 Million | -0.582x | -56.97% |
| 2007-12-31 | $31.03 Million | $-11.51 Million | -0.371x | -23.80% |
| 2006-12-31 | $23.50 Million | $-7.04 Million | -0.300x | +42.99% |
| 2005-12-31 | $23.47 Million | $-12.34 Million | -0.526x | -20.20% |
| 2004-12-31 | $15.55 Million | $-6.80 Million | -0.437x | -139.45% |
| 2003-12-31 | $15.05 Million | $-2.75 Million | -0.183x | +86.28% |
| 2002-12-31 | $3.73 Million | $-4.96 Million | -1.331x | +21.06% |
| 2001-12-31 | $4.96 Million | $-8.37 Million | -1.687x | -89.75% |
| 2000-12-31 | $9.89 Million | $-8.79 Million | -0.889x | -66.92% |
| 1999-12-31 | $11.83 Million | $-6.30 Million | -0.532x | +29.85% |
| 1998-12-31 | $8.30 Million | $-6.30 Million | -0.759x | -- |
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA s… Read more